Footnotes
National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007
[1]
Submission 4, p.1 (DoHA).
[2]
Explanatory Memorandum, p.1.
[3]
Since August 2005, a 12.5 per cent reduction has been required when the
first new brand of a drug is listed on the PBS.
[4]
Submission 4, pp.13-14 (DoHA).
[5]
Submission 4, pp.19-20 (DoHA).
[6]
Second Reading Speech, p.8.
[7]
An estimated further 33 millions prescriptions for PBS listed drugs were
dispensed at a cost less than the general patient co-payment and so do not
appear in official PBS statistics as their entire cost was met by the patient.
[8]
Submission 4, p.3 (DoHA).
[9]
Submission 4, p.6 (DoHA).
[10]
Submission 4, pp.5-6 (DoHA).
[11]
Submission 4, p.7 (DoHA).
[12]
Second Reading Speech, p.3.
[13]
Second Reading Speech, p.2.
[14]
Submission 2, p.1 (AMA).
[15]
Submission 7, pp.1-2 (Pharmacy Guild of Australia).
[16]
Submission 6. p.3 (Medicines Australia).
[17]
Submission 5, p.2 (GMiA).
[18]
Committee Hansard 15.6.07, p.46 (DoHA).
[19]
Committee Hansard 15.6.07, p.46 (DoHA).
[20]
Committee Hansard 15.6.07, p.7 (Dr T Faunce).
[21]
Submission 1, p.14 (Dr T Faunce).
[22]
Committee Hansard 15.6.07, p.6 (Dr T Faunce).
[23]
Submission 1, p.5 (Dr T Faunce).
[24]
Submission 5, pp.2-3 (GMiA).
[25]
Submission 5, p.3 (GMiA).
[26]
Committee Hansard 15.6.07, p.42 (DoHA).
[27]
Committee Hansard 15.6.07, pp.42-43 (DoHA); see also Committee
Hansard 15.6.07, pp.49-50 (DoHA).
[28]
Committee Hansard 15.6.07, p.52 (DoHA).
[29]
Committee Hansard 15.6.07, p.51 (DoHA).
[30]
Committee Hansard 15.6.07, p.52 (DoHA).
[31]
Submission 5, p.4 (GMiA).
[32]
Submission 5, pp.5-6 (GMiA).
[33]
Committee Hansard 15.6.07, p.47 (DoHA).
[34]
Committee Hansard 15.6.07, p.24 (GMiA); see also Committee
Hansard 15.6.07, p.26 (GMiA).
[35]
Submission 5, p.6 (GMiA).
[36]
Committee Hansard 15.6.07, p.7 (Dr T Faunce).
[37]
Committee Hansard 15.6.07, p.37 (Medicines Australia).
[38]
Committee Hansard 15.6.07, p.43 (DoHA).
[39]
Submission 9, p.2 (CHF).
[40]
Submission 5, p.4 (GMiA).
[41]
Submission 5, p.2 (GMiA).
[42]
Submission 5, p.2 (GMiA).
[43]
Committee Hansard 15.6.07, p.9 (Dr K Harvey).
[44]
Committee Hansard 15.6.07, p.48 (DoHA).
[45]
Submission 6, p.5 (Medicines Australia).
[46]
Submission 6, pp.6-7 (Medicines Australia).
[47]
Committee Hansard 15.6.07, p.43 (DoHA).
[48]
Submission 6, p.8 (Medicines Australia).
[49]
Submission 6, pp.8-14 (Medicines Australia).
[50]
Submission 5, p.4 (GMiA).
[51]
Submission 9, p.2 (CHF).
[52]
Committee Hansard 15.6.07. pp.43-44 (DoHA).
[53]
Submission 8, p.1 (Amgen Australia).
[54]
Submission 6, pp.14-15 (Medicines Australia).
[55]
Committee Hansard 15.6.07, pp.44-45 (DoHA).
[56]
Submission 5, p.6 (GMiA).
[57]
Committee Hansard 15.6.07, pp.45-46 (DoHA).
[58]
Submission 2, p.2 (AMA).
[59]
Submission 9, p.2 (CHF).
[60]
Submission 9, p.2 (CHF).